 Home > Biochemistry News > Biotechnology News > Studies have found that the persistent presence of antibodies in COVID-19 patients can reduce the risk of reinfection for up to six months

Studies have found that the persistent presence of antibodies in COVID-19 patients can reduce the risk of reinfection for up to six months

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

phenol ir spectrum

food research

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Researchers analyzed nearly 130 COVID-19 patients who were confirmed by PCR 3 to 6 months after the initial infection

The results published in the "Microbiology Spectrum" (Microbiology Spectrum) showed that about 90% of the participants had a spike protein and nucleocapsid antibody response, and all but one had sustained antibody levels during follow-up

Charles Schuler, MD, the first author of the paper and a clinical assistant professor of allergy and immunology at the University of Michigan Medical School, said: "In the past, people were very worried that only those patients with severe COVID-19 would have a strong infection.

Participants in this prospective study are either medical staff from the Medical College of Michigan or high-risk patients exposed to COVID-19

During the observation period, subjects who did not develop antibodies were re-infected, while there were 15 cases of antibody-negative patients

"Although some studies have shown that antibodies against COVID-19 will weaken over time, the findings of this study provide strong prospective evidence for the long-term immunity of those who have developed an immune response to minor infections

Impact on COVID-19 vaccination

The research team is currently analyzing samples taken one year after infection to further evaluate the antibody response

A study conducted in Kentucky found that people who have been infected with COVID-19 are not vaccinated and are 2.

In addition, this study was conducted from March 2020 to February 2021.

Schuler said that as the number of cases and hospitalizations increases, continuing to be unvaccinated will pay a "high price" for getting immunized

He said: "These results are encouraging for those who have already experienced the challenge of COVID-19 infection

Journal Reference :

Charles F.

Michigan Medicine-University of Michigan.

Michigan Medicine-University of Michigan.
"COVID-19 antibodies persist, reduce reinfection risk for up to six months, study finds: The antibodies' ability to neutralize COVID-19 did not differ significantly over the six-month period.
.
" ScienceDaily.
(accessed September 14, 2021).

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.